Observing the progression and regression of HELLP syndrome in pregnant women
Biological Evolution of HELLP Syndrome
This study looks at how HELLP syndrome changes in pregnant women in the ICU to better understand its effects and complications over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Sex | Female |
| Sponsor | CHU Mohammed VI Marrakech Academic / other |
| Locations | 1 site (Marrakech, Marrakech - Safi) |
| Trial ID | NCT06758960 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the biological progression and regression of HELLP syndrome in pregnant women admitted to the maternal ICU. It involves comprehensive data collection, including reviews of pathological histories, monitoring of biological parameters, and documentation of transfusion events and corticosteroid administration. The study focuses on understanding the clinical presentation and complications associated with HELLP syndrome and preeclampsia over time.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women admitted to the maternal ICU with a diagnosis of biological HELLP syndrome.
Not a fit: Patients whose symptoms are due to other conditions or who have undergone plasma exchange therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management and outcomes of pregnant women suffering from HELLP syndrome.
How similar studies have performed: While there have been studies on HELLP syndrome, this specific observational approach focusing on biological parameters is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant women who are admitted to the maternal ICU for a biological HELLP syndrome Exclusion Criteria: * Patients whose biological presentation was attributable to other conditions, such as microangiopathies or leukemia. * Patients who benefited from plasma exchange therapy
Where this trial is running
Marrakech, Marrakech - Safi
- CHU Mohammed VI of Marrakech — Marrakech, Marrakech - Safi, Morocco (Recruiting)
Study contacts
- Study coordinator: Nizar Amllah, M.D
- Email: nizaramllah@gmail.com
- Phone: +212 613069684
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.